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Plasma membrane recovery kinetics of a
microfluidic intracellular delivery platform†
Armon Sharei,‡ Roberta Poceviciute,‡ Emily L. Jackson, Nahyun Cho, Shirley Mao,
George C. Hartoularos, Derek Y. Jang, Siddharth Jhunjhunwala, Alexandra Eyerman,
Taylor Schoettle, Robert Langer* and Klavs F. Jensen*
Intracellular delivery of materials is a challenge in research and therapeutic applications. Physical
methods of plasma membrane disruption have recently emerged as an approach to facilitate the
delivery of a variety of macromolecules to a range of cell types. We use the microfluidic CellSqueeze
delivery platform to examine the kinetics of plasma membrane recovery after disruption and its
dependence on the calcium content of the surrounding buﬀer (recovery time B5 min without calcium
vs. B30 s with calcium). Moreover, we illustrate that manipulation of the membrane repair kinetics can
yield up to 5 improvement in delivery eﬃciency without significantly impacting cell viability. Membrane
repair characteristics initially observed in HeLa cells are shown to translate to primary naı¨ve murine
T cells. Subsequent manipulation of membrane repair kinetics also enables the delivery of larger
materials, such as antibodies, to these diﬃcult to manipulate cells. This work provides insight into the
membrane repair process in response to mechanical delivery and could potentially enable the
development of improved delivery methods.
Insight, innovation, integration
Physical approaches to intracellular delivery could potentially overcome many of the challenges associated with vector-based and chemical delivery methods.
However, the mechanism of plasma membrane disruption and recovery in physical methods is poorly understood. We describe a new generation of
intracellular delivery devices that are used to characterize the process of membrane disruption/repair. Calcium is identified as an important factor that
mediates membrane repair thus providing insight into parameters that may govern the performance of other physical approaches, such as ultrasound,
electroporation, fluid shear, and nanowire-based methods. This work could potentially enable the design of more eﬀective delivery systems and thus help
overcome some of the challenges of intracellular delivery in both research and clinical applications.
Introduction
Intracellular delivery of macromolecules is a challenge in
research and clinical applications. Various methods have been
developed to address this issue however each approach has
particular advantages and disadvantages. Nanoparticle1,2 and
liposome3 based approaches, for example, have demonstrated
some eﬃcacy in delivering materials to established cell lines,
but they often struggle to translate to primary cells, especially
stem cells4 and immune cells,5 and can suﬀer from oﬀ-target
eﬀects. Moreover, the techniques often rely on ineﬃcient
endosome escape mechanisms that can lose B70% of the
delivered material.6,7 Viral vectors can be eﬀective for some
gene delivery applications; however, they tend to be limited to
nucleic acid delivery and raise safety concerns in clinical
applications.8,9 Alternatively, cell penetrating peptides can be
eﬀective for some protein delivery applications although they
also suﬀer from the same endosome escape problems as
nanoparticle-based approaches.10,11
Physical approaches to delivery are potentially more robust
and could overcome some of the challenges associated with
vector-based and chemical methods.12 Electroporation,13,14 for
example, has demonstrated eﬃcacy in previously challenging
primary cells. Sonoporation has also begun to show promise in
some applications.15 Because these methods are based on
physical disruption of the plasma membrane, they provide
direct access to the cell cytoplasm. In contrast, the aforemen-
tioned chemical and vector-based techniques typically rely on
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less eﬃcient endosome escape mechanisms that hinder their
ability to translate to diﬀerent materials and cell types.
The recently described CellSqueeze microfluidic platform
has emerged as a robust physical approach to intracellular
delivery.16–19 Mechanically inducing disruption of the plasma
membrane enables passive diffusion of the target material into
the cell cytoplasm. This approach obviates the need for exo-
genous materials or fields to facilitate delivery and has demon-
strated its efficacy in cell reprogramming (10–100 improved
efficiency)19 and single-molecule imaging applications.20 How-
ever, the mechanism of membrane disruption and repair is
poorly understood.
In this work, we develop improved versions of the platform
and studied membrane repair in response to cell squeezing.
Specifically, we conduct experiments to elucidate the potential
dependence of the repair process on calcium. Other membrane
repair studies have indicated that calcium signaling is an
important component in repairing large membrane disrup-
tions, while it does not necessarily participate in the closure
of smaller pores (o0.2 mm).21,22 Thus, analysis of the calcium
dependence of the repair process would potentially support the
membrane disruption/repair delivery hypothesis (versus endo-
cytosis for example), provide some insight into the size range of




HeLa cells were cultured in Dulbecco’s Modified Eagle Medium
(DMEM) (Invitrogen, USA) supplemented with 10% fetal bovine
serum (Invitrogen, USA) and 1% penicillin/streptomycin
(Sigma, USA). One day before delivery, 3  106 cells were seeded
into a 750 cm2 tissue culture flask. Before the experiment, cells
were detached from the tissue culture flask: old medium was
removed; the cells were washed with 5 mL of PBS (Invitrogen,
USA), incubated with 5 mL of 0.5% trypsin/EDTA (Invitrogen,
USA) at 37 1C for 10 min, and neutralized with 10 mL of fresh
medium. The resulting cell suspension was split equally into as
many tubes as there were experimental conditions. The tubes
were spun at 800g for 5 min, the supernatant was discarded,
and the cell pellet was resuspended in a buﬀer of interest to
yield a final cell concentration of 3  106 cells per mL.
Delivery procedure
Delivery experiments were conducted as described previously.23
Briefly, the suspension of cells and delivery material was
passed through the device at the desired pressure. Treated cells
(60–80 mL per sample) were collected in a 96-well plate and
allowed to recover for >5 min at room temperature. Fresh
cell culture medium was then added to cells prior to fur-
ther processing or overnight culture. The microfluidic
devices used in these experiments were obtained from SQZ
Biotechnologies, USA.
Device comparison
Cell suspensions were prepared in PBS with the following
material concentrations: 0.1 mg mL1 3 kDa cascade blue
dextran, 0.1 mg mL1 70 kDa fluorescein labeled dextran, and
0.05 mg mL1 APC labeled IgG1 isotype control antibody.
The cells were passed through the device at three diﬀerent
pressures (30, 50, and 70 psi) using four diﬀerent device types
(10-7, 10-6, 50-6, 10-65). Treated cells were incubated for
B5 min post-delivery to ensure appropriate membrane recov-
ery. FACS analysis was performed the same day. Three controls
were used: untreated cells not exposed to the dye solution,
untreated cells exposed to the dye solution, and cells treated at
30 psi without exposure to the dye solution.
Buﬀer comparison
Cell suspensions were prepared in three buﬀers: PBS, DMEM,
and a third buﬀer (1.8 mM CaCl2 in PBS, 1.8 mM EDTA in PBS,
2.7 mM NaCl in PBS, or medium). Delivery materials were
added at the concentrations indicated previously. The cells
were passed through the device at four diﬀerent pressures
(30, 50, 70, and 100 psi). FACS analysis was performed the next
day. Two controls were used: untreated cells not exposed to the
dye solution and untreated cells exposed to the dye solution.
Calcium dosage
Cell suspensions were prepared in four buﬀers: PBS, 1.8 mMCaCl2
in PBS, 0.9 mM CaCl2 in PBS, and 0.18 mM CaCl2 in PBS. Delivery
materials were added at the concentrations indicated previously.
The cells were passed through the device at four diﬀerent pres-
sures (30, 50, 70, and 100 psi). FACS analysis was performed the
next day. Two controls were used: untreated cells not exposed to
the dye solution and untreated cells exposed to the dye solution.
Membrane recovery kinetics
The cell suspension was prepared in a single buﬀer (PBS,
DMEM, or 1.8 mM CaCl2 in PBS) in the absence of any delivery
material. For a zero time point, the delivery material was added
to yield the final dye concentration and immediately treated by
the device at 70 psi. For subsequent time points, the cell
suspension alone was passed through the device at 70 psi,
and the dye solution was added at set time points (15 s, 30 s,
45 s, 1 min, 1.5 min, 2 min, 3 min, 5 min, and 10 min) to yield
the same final dye concentrations indicated previously. Treated
cells were incubated with the dyes for >5 min post-exposure. In
experiments with HeLa cells, FACS analysis was performed the
next day, whereas in experiments with naı¨ve murine T cells
FACS analysis was performed the same day (due to the chal-
lenge of culturing primary naı¨ve T cells). Three controls were
used: untreated cells not exposed to the dye solution, untreated
cells exposed to the dye solution, and cells treated at 70 psi not
exposed to the dye solution.
FACS sample preparation and analysis
Samples were prepared in a 96-well v-bottom plate and washed
with 150 mL of PBS per well. The cells were suspended in FACS
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buﬀer (3% FBS, 1% pluronics, 1% PI in DPBS, 100 mL per well)
prior to analysis.
Samples were processed on a FACS Canto or LSR Fortessa
analyzer (Becton-Dickinson, USA). Results were analyzed using
FACS Diva (Becton-Dickinson, USA) and FlowJo software
(Treestar, USA).
T cell isolation
Spleens were harvested from male C57BL6 mice (Jackson Labs,
USA) at 6–12 weeks of age. Spleens were mechanically disrupted
by grinding using a pair of serrated tweezers to yield a cell
suspension of splenocytes. The suspension was passed through
a 40 mm filter to eliminate any aggregates, and red blood cell lysis
was performed according to instructions (Cat no. 00-4333-57,
eBioscience, USA). After lysis, cells were concentrated to 2  108
cells per mL. T cells were isolated using the EasySep T cell
isolation kit with the manufacturer’s protocol (Cat no. 19851,
StemCell Technologies, USA). The separation process is a nega-
tive selection, thus the isolated T cells did not have any magnetic
particles bound to them. Purified T cells were then suspended in
the desired buffer for device treatment.
Results and discussion
Performance characterization
As described previously, the CellSqueeze platform relies on
rapid mechanical deformation of a cell as it passes through a
microfluidic constriction to induce membrane disruption.19
Although current manifestations of the system require each
cell to be treated individually by the constriction, paralleliza-
tion of the approach has enabled us to operate the system with
high throughputs (50 000–500 000 cells per second). This par-
allelization strategy can lead to heterogeneity in treatment
across channels as the fluid flow profile through different
channels could be affected by their relative positions. As the
cell speed has been shown to be an important parameter in
determining the delivery efficiency and cell viability,19 differ-
ences in cell speed across channels can potentially lead to
significant heterogeneity in the treated cell population. To
address this concern, we developed a new generation of devices
designed to increase throughput and treatment homogeneity.
The device design, described in Fig. 1a and b, divides the cell
flow in two stages and is symmetrical. Compared to the
previously described system, these devices have higher
throughput (B6 at a given operating pressure), can accom-
modate cell flow in either direction, and provide more homo-
genous treatment (Fig. S1 and Table S1, ESI†). The measured
cell recovery rates for these device designs were over 90%
(Fig. S2, ESI†).
Having reduced process variability due to diﬀerential flow
speeds, we conducted characterization studies of the new designs
using HeLa cells as a model. In these studies, we designed devices
with diﬀerent constriction lengths, widths and number of
constrictions in series. The design nomenclature is defined as
(constriction length)  (constriction width)  (number of
constrictions in series). Fluorescently labeled dextran polymers
and isotype control antibodies were used to assess the delivery
eﬃciency for diﬀerent sized target molecules (Fig. 2). For a given
constriction width, increasing channel length or number of con-
strictions in series increases the delivery eﬃciency and reduces the
cell viability. Increasing operating pressure (or cell speed) also
increased the delivery eﬃciency across designs (Fig. S3 and S4,
ESI†). The 10-65 design appears to be harsher than the 50-6
design (i.e. providing higher delivery and lower viability), suggesting
that placing multiple 10 mm length constrictions in series is more
eﬀective for membrane disruption than generating a single con-
striction of equivalent total length. In comparison to the previously
reported design scheme,19 the devices described herein also exhib-
ited a more uniform distribution of delivery material (Fig. 2),
suggesting that heterogeneity amongst the treated population
may have been partially mitigated by this approach.
Calcium dependent delivery
To better understand the process of membrane recovery post-
treatment, we designed experiments to characterize recovery
kinetics and its dependence on buﬀer composition, specifically
Fig. 1 Overview of device design and investigated parameters. (a) A
schematic of the device design and the relative positioning of individual
channels. Each device is symmetrical and consists of two access holes on
each side for cells to enter and exit the device. The flow is first split into 15
separate channels and subsequently further subdivided into 5 channels,
each containing a constriction. The width of the channel prior to the
constriction point is 30 mm. (b) Image of a device implemented in glass and
silicon. Scale bar is 2 mm. (c) An illustration of the delivery process. The
membrane of the target cell is disrupted after treatment by the constric-
tion and the material in the surrounding buﬀer can diﬀuse into the cell for
the duration of the membrane recovery phase.
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calcium content. Previous studies have reported that the closure
of physically generated membrane disruptions could be governed
by thermodynamic rearrangement of the cell membrane or by
calcium mediated signaling to active membrane recovery pro-
cesses.21 These studies also indicate that holes greater than
B200 nm in size are primarily addressed through active recovery
mechanisms while those below that range are primarily addressed
through thermodynamic rearrangement. We conducted experi-
ments in buﬀers with and without calcium to gauge the depen-
dence of delivery on the presence of the ion.
The results in Fig. 3 demonstrate that cells treated by a 50-6
device in PBS receive more dextran than those treated in PBS
with 1.8 mM calcium (physiological calcium concentration is
1–2 mM24,25). A similar difference is observed when comparing
full culture media and DMEM to PBS, indicating that their calcium
content is likely the major determinant of the observed delivery
behaviour (Fig. S5, ESI†). Further studies indicated that the
aforementioned calcium response is dose dependent (Fig. 3c)
and cannot be recreated by the addition of an alternative cation,
such as sodium (Fig. S7, ESI†). These results are consistent with
previous reports of calcium mediated membrane repair.21,26
Membrane recovery kinetics
To confirm that the observed calcium eﬀects are correlated to
membrane repair behaviour we examined the rate of repair in
response to membrane disruption in diﬀerent buﬀers. The
CellSqueeze platform was suitable for these studies as the
treatment duration for a given sample is 0.5–10 s, thereby
allowing for follow-up soon after membrane disruption. In
these experiments, cells were initially treated by the device in
the absence of dextran and subsequently exposed to dextran at
defined time points. The intensity of dextran fluorescence in
cells at a given time point should correlate to the extent of
membrane disruption that persisted since the initial treatment.
These data demonstrate that cells treated in the presence of
calcium appear to seal their membranes within 15–30 s,
whereas those treated in PBS alone are not fully closed even
3 min after treatment (Fig. 4a and b). This delay in membrane
repair could account for the difference in delivery efficiency
described earlier (Fig. 3) and was observed in both the 10-6 and
50-6 designs (Fig. 4c).
These data suggest that membrane recovery post-treatment is
an active, calcium-mediated, process. Indeed, further studies with
Fig. 2 Delivery performance across device designs. HeLa cells were treated by 4 diﬀerent device designs to deliver: (a) cascade blue conjugated 3 kDa
dextran, (b) fluorescein conjugated 70 kDa dextran, and (c) an APC conjugated IgG1 isotype control antibody. The three materials were delivered
simultaneously and the results were measured by flow cytometry. 10-65 devices demonstrated the highest delivery eﬃciency, while 10-7 devices
demonstrated the lowest eﬃciency of the designs tested. Control samples were incubated with the delivery mixture for the duration of the experiment to
account for autofluorescence, endocytosis and surface binding of the target materials. The displayed data are obtained from a representative case of our
triplicate data set (Fig. S3 and S4, ESI†).
Fig. 3 Delivery by cell squeezing is calcium dependent. (a) Representative
images from cells treated by a 50-6 device. Images were obtained on the
day of treatment. Intracellular delivery of 3 kDa Alexa Fluor 488 conjugated
dextran and 10 kDa tetramethyl rhodamine conjugated dextran was
measured by fluorescence microscopy. The PBS + Ca buﬀer consisted
of PBS supplemented with 1.8 mM of calcium. Scale bars are 200 mm.
(b) Normalized delivery intensity of HeLa cells treated in diﬀerent buﬀers.
Experiments were conducted in PBS, PBS + Ca, and Dulbecco’s modified
eagle medium (DMEM). Corresponding viability data are presented in
Fig. S6 (ESI†). (c) Normalized delivery intensity of HeLa cells treated in
PBS containing diﬀerent concentrations of calcium. The experiments were
conducted across diﬀerent operating pressures to confirm that the results
were consistent across conditions. The mean intensity of cascade blue
conjugated 3 kDa dextran was measured by flow cytometry and normalized
against the control to account for background eﬀects (e.g. endocytosis
and surface binding). Error bars represent 2 standard deviations among
triplicates.
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cells treated at refrigerated temperatures (i.e. on ice) indicated
that membrane repair may be retarded relative to treatment under
ambient conditions (Fig. S9, ESI†). Although changes in tempera-
ture can influence many cell properties, low temperatures do
reduce cell activity27 and thus these results would be consistent
with the active membrane recovery hypothesis.
To examine the applicability of these findings to primary
cells, we conducted experiments in naı¨ve T cells derived from the
lymph nodes and spleen of C57BL6 mice. These experiments
demonstrate that a similar calcium (Fig. 5a and b, Fig. S10, ESI†)
and temperature dependence (Fig. S11, ESI†) is observed in
primary naı¨ve T cells. This insight into membrane recovery
enabled us to develop protocols that facilitate the delivery of
antibodies to primary naı¨ve T cells with up to 54% eﬃciency,
while maintaining 56% viability (Fig. 5c and Fig. S12, ESI†).
Conclusions
In this work, we describe a new generation of intracellular
delivery devices that provide higher throughput (B6) and
more uniform treatment (Fig. 1, Fig. S1 and Table S1, ESI†).
These devices are used to characterize the process of mem-
brane disruption/repair and its dependence on constriction
geometry, flow rate, and buﬀer composition. Calcium is identi-
fied as an important parameter that mediates membrane repair
thus indicating that the disruptions generated by this techni-
que are potentially over 200 nm in size21 (Fig. 3). Characteriza-
tion of the kinetics of delivery and membrane repair is of value
to the field as it provides insight into parameters that may
govern the performance of other physical approaches to intra-
cellular delivery, such as ultrasound,15 fluid shear,28 and
nanowire-based29 methods. Indeed these data indicate that
the calcium composition of the buﬀer (Fig. 3), temperature
(Fig. S9 and S11, ESI†), and incubation time post-treatment
(Fig. 4) are important determinants of treatment eﬃcacy.
The gained insight into membrane repair kinetics enabled
us to evolve our technique to potentially address the challenge
of protein delivery to T cells (Fig. 5). Moreover, the consistency
of the observed phenomena across HeLa cells and naı¨ve T cells,
coupled with the reported ubiquity of the calcium-mediated
membrane repair mechanism,21,22 would suggest that the
aforementioned parameters are potentially relevant to a broad
range of cell types.
Fig. 4 Pore closure kinetics are calcium dependent. (a) Normalized intensity of HeLa cells treated in the absence of dyes and subsequently exposed to
cascade blue conjugated 3 kDa dextran at the specified time points. PBS, PBS supplemented with 1.8 mM of calcium, and (b) DMEM were used as buﬀers
during these experiments. (c) Treatment of HeLa cells by a 50-6 and a 10-6 device is also compared in a PBS buﬀer. The mean intensity of cascade blue
conjugated 3 kDa dextran was measured by flow cytometry and normalized against the control to account for background eﬀects (e.g. endocytosis and
surface binding). Error bars represent 2 standard deviations among triplicates. Corresponding viability data are presented in Fig. S8 (ESI†).
Fig. 5 Translation to primary naı¨ve murine T cells. Naı¨ve murine T cells were treated by a 30-4 device in the absence of dyes and subsequently exposed to
cascade blue conjugated 3 kDa dextran at the specified times. (a) PBS and (b) PBS supplemented with 1.8 mM of calcium were used as delivery buﬀers to
compare membrane recovery kinetics. (c) Delivery of APC conjugated IgG1 isotype control antibodies to naı¨ve murine T cells by a 30-4 device run on ice.
Control samples were incubated with the delivery mixture for the duration of the experiment to account for autofluorescence, endocytosis and surface
binding of the target materials. The displayed data were obtained from a representative case of our triplicate data set by flow cytometry (Fig. S10, ESI†).
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Our work highlights the importance of membrane recovery and
how careful manipulation of delivery conditions can improve
performance without sacrificing cell viability. The described experi-
ments also underscore the potential utility of this approach in
studying membrane repair kinetics and its associated pathways,
such as vesicular exocytosis,30 to better understand repair mechan-
isms in healthy and diseased cells. Future work with this platform
could help elucidate the potential role of other ions and proteins,
such asmagnesium and calmodulin,31 through siRNA gene knock-
down, antibody-based pathway inhibition, and buﬀer composition
studies. A deeper understanding of the membrane repair process
could potentially enable the design of more eﬀective delivery
methods and thus help overcome some of the challenges of
intracellular delivery in both research and clinical applications.
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